Publication

Article

Pharmacy Times

November 2021
Volume87
Issue 11

Generic Product News November 2021

Mycophenolate Mofetil for Oral Suspension

Marketed by Lannett

Compare To: CellCept

Lannett’s mycophenolate mofetil for oral suspension 200 mg/mL has received first-cycle approval from the FDA. It is equivalent to CellCept oral suspension 200 mg/mL. The oral suspension helps prevent organ rejection in allogeneic heart, kidney, or liver transplant recipients, according to a company statement. It is to be used with other immune suppressants and is a new dosage for Lannett. It can be prescribed for individuals 3 months and older.

FOR MORE INFORMATION:

lannett.com

Deferasirox Tablets

Marketed by Camber Pharmaceuticals

Compare to: Jadenu

Camber Pharmaceuticals has added deferasirox tablets, the generic equivalent of Jadenu, to its lineup. Deferasirox is used to treat iron overload caused by blood transfusions and chronic iron overload syndrome caused by a genetic blood disorder. The tablets come in 90-mg, 180-mg, and 360-mg dosages in 30-count bottles. It has been approved for use in individuals 2 years or older who have iron overload caused by blood transfusion and for individuals 10 years or older with chronic iron overload syndrome.

FOR MORE INFORMATION:

camberpharma.com

Carbamazepine Tablets

Marketed by VGYAAN

Compare to: Tegretol

The FDA has approved carbamazepine tablets 200 mg
from VGYAAN Pharmaceuticals. The medication is for use in individuals with partial, generalized, tonic-clonic, and mixed seizures, and trigeminal and glossopharyngeal neuralgia nerve pain, according to a company statement. It is the generic equivalent of Tegretol 200 mg.

FOR MORE INFORMATION:

vgyaan.com

Reddy-Lenalidomide

Marketed by Dr. Reddy’s

Compare to: Revlimid

Reddy-Lenalidomide, a generic equivalent to Revlimid, has been approved by Health Canada, according to a statement from Dr. Reddy’s Laboratories. The medication is used
to treat individuals with transfusion-dependent anemia because of low or intermediate 1-risk myelodysplastic syndromes from a deletion 5q cytogenetic abnormality with or without cytogenetic abnormalities. It is available in 2.5-mg, 5-mg, 10-mg, 15-mg, 20-mg, and 25-mg strength capsules in blister packs.

FOR MORE INFORMATION:

drreddys.com

Related Videos